Meeting
2015 Gastrointestinal Cancers Symposium
A phase II, open-label, randomized clinical trial of panitumumab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment in advanced biliary tract cancer: The Vecti-BIL study.
Authors
Francesco Leone
Medical Oncology, University of Turin Medical School, Candiolo Cancer Institute, FPO, IRCCS, Candiolo, Italy
Francesco Leone , Donatella Marino , Roberto Filippi , Stefano Cereda , Carmen Belli , Rosella Spadi , Guglielmo Nasti , Massimo Montano , Alessio Amatu , Giuseppe Aprile , Celeste Cagnazzo , Gianpiero Fasola , Salvatore Siena , Libero Ciuffreda , Michele Reni , Massimo Aglietta
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Clinical Trial Registration Number
NCT01389414
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 281)
DOI
10.1200/jco.2015.33.3_suppl.281
Abstract #
281
Poster Bd #
B2
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
A single-arm phase II trial of gemcitabine, oxaliplatin, and panitumumab in KRAS wild-type advanced biliary tract cancer.
First Author: Marcus Smith Noel
Poster
2012 ASCO Annual Meeting
Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: Final analysis of a randomized phase II trial (BINGO).
First Author: David Malka
Poster
2020 Gastrointestinal Cancers Symposium
SHR-1210 combined with GEMOX as first-line treatment in patients with advanced biliary tract cancer.
First Author: Xiaofeng Chen
Poster
2015 ASCO Annual Meeting
Randomized phase II crossover trial exploring the clinical benefit from targeting EGFR or VEGF with combination chemotherapy in patients with non-resectable biliary tract cancer.
First Author: Lars Henrik Jensen